东宝生物(300239) - 2020 Q3 - 季度财报

Financial Performance - Operating revenue for the current period was ¥114,287,205, representing a year-on-year increase of 5.75%[7] - Net profit attributable to shareholders decreased by 37.17% to ¥3,769,212.7 compared to the same period last year[7] - The basic earnings per share fell by 46.27% to ¥0.0072, while diluted earnings per share also decreased by the same percentage[7] - The company reported total operating revenue of CNY 301,069,330.26, a decrease of 11.22% compared to the same period last year[22] - Net profit attributable to shareholders was CNY 10,548,260.63, down 55.49% year-on-year[22] - The company reported a net profit margin improvement, with retained earnings at CNY 122,877,101.18 compared to CNY 129,758,258.26 in the previous period[52] - The total profit for the third quarter was CNY 4,365,565.00, down from CNY 7,008,213.04, reflecting a decline of about 37.5%[56] - The total profit for Q3 2020 was CNY 12.28 million, down 54.8% from CNY 27.16 million in Q3 2019[68] Cash Flow and Assets - The net cash flow from operating activities improved significantly, showing a 161.40% increase to ¥33,666,270[7] - The cash inflow from operating activities for the period was CNY 273,917,078.34, compared to CNY 202,614,268.60 in the previous period, representing a growth of approximately 35.2%[69] - The total cash outflow from investing activities was CNY 120,247,612.20, compared to CNY 134,285,688.90 in the previous period, indicating a decrease of about 10.5%[71] - The total cash and cash equivalents at the end of the period amounted to CNY 51,987,950.93, slightly down from CNY 54,365,916.23 at the end of the previous period[75] - Total assets at the end of the reporting period reached ¥1,403,113,232.85, an increase of 6.68% compared to the previous year[7] - As of September 30, 2020, the company's total current assets amounted to approximately CNY 490.33 million, an increase from CNY 474.11 million at the end of 2019[46] Liabilities and Equity - The company's net assets attributable to shareholders decreased by 0.49% to ¥984,196,581.94[7] - Total liabilities increased to CNY 416,749,651.14 from CNY 322,159,811.22 year-over-year[52] - Current liabilities rose to CNY 338,204,943.83, up from CNY 242,944,983.18 in the previous period[52] - The company's total equity decreased to CNY 987,235,706.03 from CNY 996,573,716.93[52] - The total equity attributable to shareholders of the parent company is CNY 989,082,880.93, indicating strong financial health[80] Inventory and Receivables - Inventory rose by 30.64% to ¥302,590,458.49, attributed to decreased sales during the COVID-19 pandemic[18] - Accounts receivable financing decreased by 81.22% to ¥12,311,132.31 from ¥65,551,538.90 due to the endorsement transfer of bank acceptance bills[18] - Accounts receivable decreased to CNY 88.52 million from CNY 102.40 million year-over-year, indicating improved collection efficiency[46] - Inventory levels increased significantly to CNY 302.59 million from CNY 231.62 million, reflecting a strategic buildup in anticipation of market demand[46] Research and Development - The company is advancing a new artificial meat project, with structural research nearly complete and equipment procurement underway[27] - The company is developing a super-low endotoxin gelatin preparation process, aimed at enhancing the medical device industry[29] - Research and development expenses were CNY 2,633,012.40, slightly down from CNY 2,648,127.86, indicating a focus on maintaining R&D investment[59] - Research and development expenses were CNY 8.34 million, slightly up from CNY 8.16 million year-over-year, showing continued investment in innovation[67] Shareholder Information - The total number of shareholders at the end of the reporting period was 30,117, with the largest shareholder holding 27.37%[10] - The company did not engage in any repurchase transactions among the top ten shareholders during the reporting period[12] - The company repurchased part of its restricted stock, reducing treasury stock by 50% to ¥2,536,560.00[19] Regulatory and Compliance - The company adjusted its financial statements to reflect the new revenue recognition standards, impacting contract liabilities and other current liabilities[81] - The company implemented new revenue recognition standards starting in 2020, adjusting advance payments to contract liabilities and other current liabilities[85] - The third quarter report was not audited[86]